129 Results for "

Fc domain

" in MedChemExpress (MCE) Product Catalog:
Products (129)

129 Results for "Fc domain" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P70665
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Fibronectin type III domain-containing protein 5; Fibronectin type III repeat-containing protein 2; Irisin; FNDC5
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99930
CAS No.: 2375240-92-7
Synonyms: AKR-001; AMG-876

Target:  

FGFR

Research Areas:  

Inflammation/Immunology

Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829
CAS No.: 332348-12-6
Purity:  ≥99.0%
Synonyms: CTLA4lg; BMS-188667

Target:  

CTLA-4

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108829A
CAS No.: 332348-12-6
Purity:  95.00%
Synonyms: CTLA4lg (powder); BMS-188667 (powder); Orencia
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801A
CAS No.: 862111-32-8
Purity:  97.66%

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease Cancer

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108801
CAS No.: 862111-32-8
Synonyms: VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

Target:  

VEGFR

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99777
CAS No.: 2131089-46-6
Synonyms: TTI-621

Target:  

CD47

Research Areas:  

Cancer

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99437
CAS No.: 2367012-88-0
Synonyms: KN-026

Target:  

EGFR

Research Areas:  

Cancer

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P75335
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: C-type lectin domain family 1 member B; CLEC1B; CLEC2
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70101
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuC-type lectin domain family 7 member A/Dectin-1, Fc; Beta-glucan receptor; BGR; CD369; CLEC7A; CLECSF12; CLECSF12DC-associated C-type lectin 1; Dectin1; Dectin-1; DECTIN1CANDF4
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P990688
CAS No.: 2559056-68-5
Synonyms: AMG-509

Target:  

CD3

Research Areas:  

Cancer

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
loading...
    loading...
Cat. No.: HY-P99115
CAS No.: 2102192-68-5
Synonyms: ASC 22; KN 035

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P990706
CAS No.: 2490217-42-8
Synonyms: ALPN-303

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P99518
CAS No.: 1580555-26-5
Synonyms: BMS 986089; RG 6206; RO 7239361; BHV2000

Target:  

TGF-beta/Smad

Research Areas:  

Others

Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a protein that blocks myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
loading...
    loading...
Cat. No.: HY-P991440

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind FcγRIa and FcγRIIa, leading to the formation of anti-drug antibodies (ADA). AMG 966 can be used in research on Crohn's disease and ulcerative colitis. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-108822
CAS No.: 501081-76-1
Purity:  ≥95.0%
Synonyms: Arcalyst; IL 1 Trap; Interleukin 1 Trap

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
loading...
    loading...
Cat. No.: HY-P99665
CAS No.: 2131038-11-2
Synonyms: LY-3209590

Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
loading...
    loading...
Cat. No.: HY-P990735
CAS No.: 2765066-99-5
Synonyms: UCB-1381

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .
loading...
    loading...
Cat. No.: HY-P99562
CAS No.: 2148354-90-7
Synonyms: XmAb-18087

Target:  

CD3

Research Areas:  

Cancer

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
loading...
    loading...
Cat. No.: HY-P99010A

Research Areas:  

Cancer

Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
loading...
    loading...